Cifu® VAD, the fully magnetically levitated ventricular assist device that was developed by BRIOHEALTH TECHNOLOGIES, was officially gained the market approval in China in November 2021. It is China's first and world's only two fully magnetically levitated LVAD, especially in terms of hemocompatibility, implantation invasiveness and operational reliability. Until the end of March 2026, the implantation operations of this product have undergone in more than 100 of China's top cardiovascular hospitals and has benefited more than 750 end-stage heart failure patients.
Besides, as China's first active implantable medical device approved by FDA for clinical trials, BrioVAD® secured Medicare coverage, with each implant covered by $220,000 in Medicare funding. Until the end of 2025, BrioVAD® has been implanted in around 150 cases across 22 U.S. clinical centers. Meanwhile, the clinical trials of this product have also begun in Europe.